Treating inflammation is the next big breakthrough in fighting vascular disease.
Our therapeutic antibody PC-mAb is a first-in-class candidate.
Vascular inflammation in immunovascular diseases is significant but is not specifically addressed by current therapies. Athera is developing one…
learn more
